A randomised controlled trial to evaluate options for second-line therapy in patients failing a first-line 2 nucleoside reverse transcriptase inhibitors (2NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen in Africa.

Trial Profile

A randomised controlled trial to evaluate options for second-line therapy in patients failing a first-line 2 nucleoside reverse transcriptase inhibitors (2NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen in Africa.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Abacavir; Non-nucleoside reverse transcriptase inhibitors; Raltegravir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms EARNEST; EARNEST-GSS-II
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2015 Primary endpoint has not been met (good disease control at week 96), as per results published in the JAIDS.
    • 16 Nov 2015 Results (assessing neurocognitive function) published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top